Products are not medicines, not supplements, and not for human consumption
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a stable fragment of a naturally occurring protein
14,28,29,30,31,32,33,34 As most of the trials compared GLP-1RA to placebo, only indirect comparisons between GLP-1RA and other glucose-lowering agents commonly used in clinical practice could be drawn from network meta-analyses
Wegovy is administered once weekly via subcutaneous injection, typically in the abdomen, thigh, or upper arm
The active molecule is shared, but manufacturing, regulatory status, and price differ between the two